Latest & greatest articles for celecoxib

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on celecoxib or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on celecoxib and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for celecoxib

21. Onsenal? (Celecoxib) withdrawn from EU market

Onsenal? (Celecoxib) withdrawn from EU market Onsenal▼ (Celecoxib) withdrawn from EU market Drug Safety Update - GOV.UK GOV.UK uses cookies to make the site simpler. Search Onsenal▼ (Celecoxib) withdrawn from EU market From: Published: 8 August 2011 Therapeutic area: Onsenal▼ (celecoxib) is no longer approved in Europe for the reduction of intestinal polyps in familial adenomatous polyposis (FAP). Article date: August 2011 Onsenal▼ withdrawal Celecoxib is a non-steroidal anti-inflammatory drug (...) and cyclo-oxygenase type 2 inhibitor, which is approved for the treatment of symptoms of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis. Until recently, celecoxib was also authorised as the orphan drug Onsenal▼ for the reduction of intestinal polyps in familial adenomatous polyposis. At the time of approval of Onsenal▼, the licence (marketing authorisation) holder committed to do post-authorisation clinical studies. However, failure to recruit sufficient numbers into a clinical trial

MHRA Drug Safety Update2011

22. Celecoxib for pain control in joint arthroplasty

Celecoxib for pain control in joint arthroplasty Celecoxib for pain control in joint arthroplasty Celecoxib for pain control in joint arthroplasty Mitchell MD, Fosnocht K, Williams K Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation Mitchell MD, Fosnocht K, Williams K. Celecoxib for pain control in joint arthroplasty. Philadelphia: Center for Evidence

Health Technology Assessment (HTA) Database.2011

23. Cost effectiveness of etoricoxib versus celecoxib and non-selective NSAIDs in the treatment of ankylosing spondylitis

Cost effectiveness of etoricoxib versus celecoxib and non-selective NSAIDs in the treatment of ankylosing spondylitis Cost effectiveness of etoricoxib versus celecoxib and non-selective NSAIDs in the treatment of ankylosing spondylitis Cost effectiveness of etoricoxib versus celecoxib and non-selective NSAIDs in the treatment of ankylosing spondylitis Jansen JP, Gaugris S, Choy EH, Ostor A, Nash JT, Stam W Record Status This is a critical abstract of an economic evaluation that meets (...) the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study evaluated the cost-effectiveness of etoricoxib compared with celecoxib, diclofenac, and naproxen for patients with ankylosing spondylitis, who required routine non-steroidal anti-inflammatory drug (NSAID) treatment. The authors concluded that their economic

NHS Economic Evaluation Database.2010

24. Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): a randomised trial.

Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): a randomised trial. 20638563 2010 07 19 2010 07 29 2015 11 19 1474-547X 376 9736 2010 Jul 17 Lancet (London, England) Lancet Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): a randomised trial. 173-9 10.1016/S0140-6736(10)60673-3 Cyclo-oxygenase (COX)-2-selective non-steroidal anti-inflammatory drugs (NSAIDs) and non-selective (...) NSAIDs plus a proton-pump inhibitor (PPI) have similar upper gastrointestinal outcomes, but risk of clinical outcomes across the entire gastrointestinal tract might be lower with selective drugs than with non-selective drugs. We aimed to compare risk of gastrointestinal events associated with celecoxib versus diclofenac slow release plus omeprazole. We undertook a 6-month, double-blind, randomised trial in patients with osteoarthritis or rheumatoid arthritis at increased gastrointestinal risk at 196

Lancet2010

25. Single dose oral celecoxib for acute postoperative pain in adults.

Single dose oral celecoxib for acute postoperative pain in adults. BACKGROUND: This is an update of a review published in The Cochrane Library, Issue 1, 2003. Celecoxib is a selective cyclo-oxygenase-2 (COX-2) inhibitor prescribed for the relief of chronic pain in osteoarthritis and rheumatoid arthritis. Celecoxib is believed to be associated with fewer upper gastrointestinal adverse effects than conventional non-steroidal anti-inflammatory drugs (NSAIDs). Its effectiveness in acute pain (...) was demonstrated in the earlier review. Additional studies have now been published for the 400 mg dose, and this updated review provides more robust estimates of efficacy and harm. OBJECTIVES: To assess analgesic efficacy and adverse effects of a single oral dose of celecoxib for moderate to severe postoperative pain. SEARCH STRATEGY: Cochrane CENTRAL, MEDLINE, EMBASE, and the Oxford Pain Database. Most recent search: July 2008. SELECTION CRITERIA: Randomised controlled trials (RCTs) of adults prescribed any

Cochrane2008

26. Cognitive function over time in the Alzheimer`s Disease Anti-inflammatory Prevention Trial (ADAPT): results of a randomized, controlled trial of naproxen and celecoxib

Cognitive function over time in the Alzheimer`s Disease Anti-inflammatory Prevention Trial (ADAPT): results of a randomized, controlled trial of naproxen and celecoxib 18474729 2008 07 15 2008 08 04 2017 02 20 1538-3687 65 7 2008 Jul Archives of neurology Arch. Neurol. Cognitive function over time in the Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT): results of a randomized, controlled trial of naproxen and celecoxib. 896-905 10.1001/archneur.2008.65.7.nct70006 Observational (...) studies have shown reduced risk of Alzheimer dementia in users of nonsteroidal anti-inflammatory drugs. To evaluate the effects of naproxen sodium and celecoxib on cognitive function in older adults. Randomized, double-masked chemoprevention trial. Six US memory clinics. Men and women aged 70 years and older with a family history of Alzheimer disease; 2117 of 2528 enrolled had follow-up cognitive assessment. Celecoxib (200 mg twice daily), naproxen sodium (220 mg twice daily), or placebo, randomly

EvidenceUpdates2008 Full Text: Link to full Text with Trip Pro

27. Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: the Cross Trial Safety Analysis

Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: the Cross Trial Safety Analysis Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: the Cross Trial Safety Analysis Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: the Cross Trial Safety Analysis Solomon SD, Wittes J, Finn PV, Fowler R, Viner J, Bertagnolli MM, Arber N, Levin B, Meinert CL, Martin B, Pater JL, Goss PE, Lance P, Obara S, Chew EY, Kim J, Arndt G, Hawk E (...) , Cross Trial Safety Assessment Group CRD summary This review concluded that the risk of experiencing a cardiovascular event was greater with higher doses of celecoxib and with a greater underlying risk of such events. Despite some limitations in the review, the conclusion seems reliable for the populations evaluated in the trials, but might not be generalisable to populations treated with celecoxib on a long-term basis. Authors' objectives To assess the cardiovascular risk associated with long-term

DARE.2008

28. Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation

Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation Cyclooxygenase-2 (...) selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation Chen Y-F, Jobanputra P, Barton P, Bryan S, Fry-Smith A, Harris G, Taylor RS Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Chen

Health Technology Assessment (HTA) Database.2008

29. Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation

Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation Cyclooxygenase-2 (...) selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation Chen Y F, Jobanputra P, Barton P, Bryan S, Fry-Smith A, Harris G, Taylor R S CRD summary This review evaluated the effectiveness of cyclooxygenase-2 (COX-2) selective non-steroidal anti-inflammatory drugs (NSAIDS) for osteoarthritis (OA) and rheumatoid arthritis (RA) patients

DARE.2008

30. Cyclooxygenase-2 selective non-steroidal anti-inflammatory (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis or rheumatoid arthritis: a systematic review and economic evaluation

Cyclooxygenase-2 selective non-steroidal anti-inflammatory (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis or rheumatoid arthritis: a systematic review and economic evaluation Cyclooxygenase-2 selective non-steroidal anti-inflammatory (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis or rheumatoid arthritis: a systematic review and economic evaluation Journals Library An error has

NIHR HTA programme2008

32. An economic model of long-term use of celecoxib in patients with osteoarthritis

An economic model of long-term use of celecoxib in patients with osteoarthritis An economic model of long-term use of celecoxib in patients with osteoarthritis An economic model of long-term use of celecoxib in patients with osteoarthritis Loyd M, Rublee D, Jacobs P Record Status This is an economic evaluation that meets the criteria for inclusion on NHS EED. Bibliographic details Loyd M, Rublee D, Jacobs P. An economic model of long-term use of celecoxib in patients with osteoarthritis. BMC (...) Gastroenterology 2007; 7: 25 PubMedID DOI Original Paper URL Indexing Status Subject indexing assigned by NLM MeSH Age Factors; Analysis of Variance; Anti-Inflammatory Agents, Non-Steroidal /economics /therapeutic use; Celecoxib; Cost-Benefit Analysis; Diclofenac /economics /therapeutic use; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Long-Term Care; Male; Maximum Tolerated Dose; Middle Aged; Models, Economic; Naproxen /economics /therapeutic use

NHS Economic Evaluation Database.2007

33. Effect of celecoxib on restenosis after coronary angioplasty with a Taxus stent (COREA-TAXUS trial): an open-label randomised controlled study.

Effect of celecoxib on restenosis after coronary angioplasty with a Taxus stent (COREA-TAXUS trial): an open-label randomised controlled study. 17707751 2007 08 20 2007 09 04 2015 11 19 1474-547X 370 9587 2007 Aug 18 Lancet (London, England) Lancet Effect of celecoxib on restenosis after coronary angioplasty with a Taxus stent (COREA-TAXUS trial): an open-label randomised controlled study. 567-74 In-vitro and animal experiments have shown that the cyclo-oxygenase 2 inhibitor celecoxib can (...) reduce formation of neointima within stents. We aimed to test whether celecoxib has similar effects in a clinical setting. In a randomised two-centre trial, we enrolled 274 patients who had angina pectoris or a positive stress test and who had native coronary artery lesions for which implantation of paclitaxel-eluting stents was feasible. All patients were given aspirin (100 mg daily) and clopidogrel (75 mg daily). 136 patients were randomly assigned to receive celecoxib (400 mg before

Lancet2007

34. Celecoxib for colorectal adenomas increased CV events

Celecoxib for colorectal adenomas increased CV events Celecoxib for colorectal adenomas increased CV events | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal (...) accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Celecoxib for colorectal adenomas increased CV events Article Text Therapeutics Celecoxib for colorectal adenomas increased CV events Free David Juurlink , MD, PhD, FRCPC Statistics from Altmetric.com No Altmetric data available for this article. Solomon SD, McMurray JJ, Pfeffer MA, et al . Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N

Evidence-Based Medicine (Requires free registration)2006

35. Risk of cardiovascular events and celecoxib: a systematic review and meta-analysis

Risk of cardiovascular events and celecoxib: a systematic review and meta-analysis Risk of cardiovascular events and celecoxib: a systematic review and meta-analysis Risk of cardiovascular events and celecoxib: a systematic review and meta-analysis Caldwell B, Aldington S, Weatherall M, Shirtcliffe P, Beasley R CRD summary This review assessed the evidence for an increased risk of cardiovascular events associated with the cyclooxygenase-2 inhibitor celecoxib. The review included a number (...) of large trials addressing diverse conditions and found that celecoxib was associated with a higher risk of myocardial infarction than placebo or any other treatment. Despite some poorly reported methodology, this conclusion is likely to be reliable. Authors' objectives To assess the risk of cardiovascular events with administration of the cyclooxygenase-2 (COX-2) specific inhibitor celecoxib. Searching MEDLINE, EMBASE, the Cochrane Database of Systematic Reviews, the Cochrane CENTRAL Register, DARE

DARE.2006

36. Celecoxib for the prevention of sporadic colorectal adenomas.

Celecoxib for the prevention of sporadic colorectal adenomas. 16943400 2006 08 31 2006 09 05 2016 06 21 1533-4406 355 9 2006 Aug 31 The New England journal of medicine N. Engl. J. Med. Celecoxib for the prevention of sporadic colorectal adenomas. 873-84 Studies showing that drugs that inhibit cyclooxygenase-2 (COX-2) reduce the number of colorectal adenomas in animals and patients with familial adenomatous polyposis suggest that COX-2 inhibitors may also prevent sporadic colorectal neoplasia (...) . We randomly assigned patients who had adenomas removed before study entry to receive placebo (679 patients) or 200 mg (685 patients) or 400 mg (671 patients) of celecoxib twice daily. Randomization was stratified for the use of low-dose aspirin. Follow-up colonoscopies were performed at one and three years after randomization. The occurrence of newly detected colorectal adenomas was compared among the groups with the life-table extension of the Mantel-Haenszel test. Follow-up colonoscopies were

NEJM2006

37. Celecoxib for the prevention of colorectal adenomatous polyps.

Celecoxib for the prevention of colorectal adenomatous polyps. 16943401 2006 08 31 2006 09 05 2015 11 19 1533-4406 355 9 2006 Aug 31 The New England journal of medicine N. Engl. J. Med. Celecoxib for the prevention of colorectal adenomatous polyps. 885-95 Overexpression of cyclooxygenase 2 (COX-2) has been associated with colorectal adenomatous polyps and cancer, prompting researchers to propose its inhibition as a chemopreventive intervention. The Prevention of Colorectal Sporadic Adenomatous (...) Polyps trial was a randomized, placebo-controlled, double-blind study of the COX-2 inhibitor celecoxib given daily in a single 400-mg dose. At 107 centers in 32 countries, we randomly assigned 1561 subjects who had had adenomas removed before enrollment to receive celecoxib (933 subjects) or placebo (628 subjects) daily, after stratification according to the use or nonuse of low-dose aspirin. The primary outcome was detection of adenomas at either year 1 or year 3 by colonoscopy and was compared

NEJM2006

38. Differences in outcomes of patients with congestive heart failure prescribed celecoxib, rofecoxib, or non-steroidal anti-inflammatory drugs: population based study.

Differences in outcomes of patients with congestive heart failure prescribed celecoxib, rofecoxib, or non-steroidal anti-inflammatory drugs: population based study. OBJECTIVES: To compare the risk of death and recurrent congestive heart failure in elderly patients prescribed celecoxib, rofecoxib, or non-steroidal anti-inflammatory drugs (NSAIDs) and to determine whether there are class differences between celecoxib and rofecoxib. DESIGN: Population based retrospective cohort study. SETTING (...) : Databases of hospital discharge summaries and prescription drug claims in Quebec. PARTICIPANTS: 2256 patients aged 66 or more prescribed celecoxib, rofecoxib, or an NSAID after an index admission for congestive heart failure between April 2000 and March 2002. MAIN OUTCOME MEASURES: Time to all cause death and recurrent congestive heart failure, combined and separately. RESULTS: The risk of death and recurrent congestive heart failure combined was higher in patients prescribed NSAIDs or rofexocib than

BMJ2005 Full Text: Link to full Text with Trip Pro

39. Patients exposed to rofecoxib and celecoxib have different odds of nonfatal myocardial infarction.

Patients exposed to rofecoxib and celecoxib have different odds of nonfatal myocardial infarction. BACKGROUND: Studies have postulated that cyclooxygenase-2 (COX-2) selective inhibitors affect cardiovascular risk through various mechanisms. Some of these mechanisms could increase risk (for example, inhibition of prostacyclin production), and some could decrease risk (for example, inhibition of inflammation). OBJECTIVE: To determine the effect of COX-2 inhibitors on risk for nonfatal (...) myocardial infarction (MI). DESIGN: Case-control study. SETTING: 36 hospitals in a 5-county area. PARTICIPANTS: 1718 case-patients with a first, nonfatal MI admitted to these hospitals and 6800 controls randomly selected from the same counties. MEASUREMENTS: Self-reported medication use assessed through telephone interviews. RESULTS: The adjusted odds ratio for MI among celecoxib users, relative to persons who did not use nonaspirin nonsteroidal anti-inflammatory drugs (NSAIDs), was 0.43 (95% CI, 0.23 to 0.79

Annals of Internal Medicine2005

40. Celecoxib for the treatment of pain in osteoarthritis and rheumatoid arthritis

Celecoxib for the treatment of pain in osteoarthritis and rheumatoid arthritis Celecoxib for the treatment of pain in osteoarthritis and rheumatoid arthritis Celecoxib for the treatment of pain in osteoarthritis and rheumatoid arthritis Moga C, Harstall C, Tang Z Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Moga C, Harstall C, Tang Z (...) . Celecoxib for the treatment of pain in osteoarthritis and rheumatoid arthritis. Edmonton: Alberta Heritage Foundation for Medical Research (AHFMR). AHFMR - Information Paper #24. 2005 Authors' objectives The objective of this review was to present the current evidence on the efficacy/effectiveness and safety of celecoxib (Celebrex (R)) for the treatment of pain in patients with osteoarthritis (OA) and rheumatoid arthritis (RA). Authors' conclusions Overall, short-term use of celecoxib was equivalent

Health Technology Assessment (HTA) Database.2005